Ricardo Pérez Rubio Flores

Dr. Ricardo Pérez Rubio Flores

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2026 in Life
Verified
Journal Article
Open access
PDF file
CRCARMEN RUBIO
CARMEN RUBIO
RFRicardo Pérez Rubio Flores
Ricardo Pérez Rubio Flores
Javier de Jesús Pérez-VillavicencioJavier de Jesús Pérez-Villavicencio
Javier de Jesús Pérez-Villavicencio
NSNorma Serrano-Garcia
Norma Serrano-Garcia
ALAngel Lee
Angel Lee
RMRubio-Osornio Moisés
Rubio-Osornio Moisés
Parkinson’s disease (PD) is defined by the progressive degeneration of dopaminergic neurons within the substantia nigra and the pathological accumulation of α-synuclein (α-syn) aggregates. Beyond these intracellular hallmarks, the extracellular matrix (ECM) has emerged as an active regulator of synaptic dysfunction, neuroinflammation, and disease progression. Recent multi-omics evidence, including transcriptomic and proteomic profiling of post-mortem tissue and iPSC-derived neurons, demonstrates consistent dysregulation of ECM components across both sporadic and genetic PD subtypes—typified by downregulation of basement membrane collagens (COL4A) and integrin signaling (ITGB1), alongside upregulation of matrix metalloproteinases (MMPs). These alterations destabilize perineuronal nets (PNNs), allow prion-like α-syn propagation, and promote glial activation through TLR-mediated signaling. Circulating ECM-derived neoepitopes (C1M, C4M) may complement neurofilament light chain as prognostic biomarkers of disease progression, although prospective validation remains necessary. Pharmacological strategies targeting MMP activity (e.g., doxycycline), integrin–FAK signaling (ATN-161), and MMP–TIMP balance (mesenchymal stem cells) represent emerging therapeutic avenues, though clinical evidence in PD remains limited. This review synthesizes current evidence on ECM dysregulation in PD and discusses its implications for biomarker development and disease-modifying intervention.

16 June 2026 in Journal of Integrative Neuroscience
Verified
Journal Article
Open access
PDF file
CRCARMEN RUBIO
CARMEN RUBIO
NSNorma Serrano-Garcia
Norma Serrano-Garcia
RFRicardo Pérez Rubio Flores
Ricardo Pérez Rubio Flores
Javier de Jesús Pérez-VillavicencioJavier de Jesús Pérez-Villavicencio
Javier de Jesús Pérez-Villavicencio
HRHéctor Romo-Parra
Héctor Romo-Parra
RMRubio-Osornio Moisés
Rubio-Osornio Moisés
Antiseizure medications (ASMs) have traditionally been characterized by their modulation of neuronal ion channels and synaptic processes; however, accumulating evidence indicates that numerous ASMs also directly modulate mitochondrial function. Specifically, several ASMs interact with ion channels located in both the inner and outer mitochondrial membranes, including the voltage-dependent anion channel (VDAC), the mitochondrial calcium uniporter (MCU), the mitochondrial Na+/Ca2+ exchanger (NCLX), the mitochondrial permeability transition pore (mPTP), and mitochondrial ATP-sensitive potassium channels (mitoKATP). Modulation of these channels regulates critical processes in epilepsy, including Ca2+ homeostasis, ATP synthesis, redox equilibrium, and susceptibility to neuronal apoptosis. Phenytoin and carbamazepine reduce voltage-dependent anion channel isoform 1 (VDAC1)-associated mitochondrial permeability by modulating the Bcl-2-associated X protein (Bax)/B-cell lymphoma 2 protein (Bcl-2) ratio; ethosuximide limits mitochondrial Ca2+ overload through modulation of the MCU complex; valproic acid stabilizes NCLX function and prevents mPTP opening via antioxidant mechanisms; levetiracetam contributes to preserving intracellular Ca2+ handling; and mitoKATP activators, including diazoxide and retigabine, promote mitochondrial membrane potential stability and reduce seizure-induced reactive oxygen species (ROS) generation. The mitochondrial effects vary according to epilepsy subtype, contributing to the attenuation of hippocampal apoptosis in temporal lobe epilepsy and thalamocortical network modulation in generalized epilepsies. In this narrative review we examine the experimental and molecular evidence demonstrating how ASMs modulate mitochondrial ion channels and how these interactions contribute to their anticonvulsant mechanisms, thereby broadening the understanding of mitochondria as key functional components in antiseizure pharmacology.

2 October 2026 in Neuroglia
Verified
Journal Article
Open access
PDF file
Javier de Jesús Pérez-VillavicencioJavier de Jesús Pérez-Villavicencio
Javier de Jesús Pérez-Villavicencio
RFRicardo Pérez Rubio Flores
Ricardo Pérez Rubio Flores
HRHéctor Romo-Parra
Héctor Romo-Parra
CRCARMEN RUBIO
CARMEN RUBIO
The cerebellum, long studied as the principal center for motor coordination, is now recognized as a participant in epileptogenic network dynamics through the pathway running from the cerebellar cortex to the deep cerebellar nuclei and on to thalamic and cortical targets. Purkinje cells are the sole inhibitory output of the cerebellar cortex, and Bergmann glia, a radial astrocyte population apposed to Purkinje cell dendrites and parallel-fiber synapses, sustain the perisynaptic environment on which Purkinje cell firing depends through glutamate clearance by GLAST/EAAT1, potassium buffering by Kir4.1, and calcium-dependent signaling. In cortex and hippocampus, loss of the equivalent functions in protoplasmic astrocytes lowers seizure threshold and produces spontaneous seizures, but no comparable experiment has been performed in Bergmann glia. Molecular genetics has identified numerous epilepsy-associated genes, of which only SLC1A3, KCNJ10 and AQP4 have cell-type-resolved expression in Bergmann glia; the remainder act on cerebellar circuits through neurons. In human epilepsy, cerebellar atrophy with Purkinje cell loss and Bergmann gliosis tracks cumulative seizure burden and antiseizure medication exposure rather than a primary cerebellar lesion and is therefore best read as reactive. Reactive astrogliosis is nonetheless accompanied by reduced glutamate transport and potassium buffering in sclerotic hippocampus, and whether cerebellar reactive gliosis carries the same homeostatic cost has not been measured. This review sets out the circuit-level, genetic and neuropathological evidence bearing on that question and specifies the experiments that would answer it.